EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Monitoring levetiracetam concentration in saliva during pregnancy is stable and feasible

Wanling Li, Ximeng Yang, Qian Chen, Zhenlei Wang, Yifei Duan, Lei Chen iD

CNS Neuroscience & Therapeutics · 2024

DOI: 10.1111/cns.14827 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Wanling Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Levetiracetam, Saliva, Anticonvulsants, Epilepsy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sichuan Science and Technology Plan Project, the Interdisciplinary Crossing and Integration of Medicine and Engineering for Talent Training Fund, West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This multicenter prospective cohort study (registration no. ChiCTR2000032089) aimed to investigate the relationship between saliva and plasma levetiracetam concentrations to determine whether saliva could be used for routine monitoring of levetiracetam during pregnancy.

Methods

The slot concentrations of levetiracetam in simultaneously obtained saliva and plasma samples were measured using UPLC–MS/MS. The correlations between saliva and plasma levetiracetam concentrations and the dose‐normalized concentrations were compared among pregnant women in different stages and nonpregnant control participants with epilepsy.

Results

In total, 231 patients with 407 plasma and saliva sample pairs were enrolled from 39 centers. Linear relationships between salivary and plasma levetiracetam concentrations were reported in the enrolled population ( r = 0.898, p < 0.001), including pregnant ( r = 0.935, p < 0.001) and nonpregnant participants ( r = 0.882, p < 0.001). Plasma concentrations were moderately higher than saliva concentrations, with ratios of saliva to plasma concentrations of 0.98 for nonpregnant women, 0.98, 1, and 1.12 for pregnant women during the first trimester, the second trimester, the and third trimester, respectively. The effective range of saliva levetiracetam concentration was found to be 9.98 μg/mL (lower limit) with an area under the curve (AUC) of 0.937 (95% confidence intervals, 0.915–0.959), sensitivity of 88.9%, specificity of 86.8%, and p < 0.001, to 24.05 μg/mL (upper limit) with an AUC of 0.952 (0.914–0.99), sensitivity of 100%, specificity of 92.3%, and p = 0.007.

Conclusion

The saliva/plasma concentration ratio of levetiracetam remains constant during pregnancy and is similar to that in non‐pregnant individuals. Monitoring levetiracetam concentration in saliva during pregnancy should be widely promoted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevetiracetamSalivaAnticonvulsantsEpilepsyHumansFemalePregnancyAdultYoung AdultDrug MonitoringPiracetamProspective StudiesCohort StudiesTandem Mass Spectrometry

Stichwörter der Autor:innen

levetiracetamplasmapregnant women with epilepsysalivatherapeutic drug monitoring

Substanzen

LevetiracetamAnticonvulsantsPiracetam

Autor:innen und Institutionen

  • Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Center of Biostatistics, Design, Measurement and Evaluation, Department of Clinical Research Management, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
  • NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Clinical Trial Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
  • Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

ORCID-Profile: Lei Chen

Förderung

  • Sichuan Science and Technology Plan Project
  • the Interdisciplinary Crossing and Integration of Medicine and Engineering for Talent Training Fund, West China Hospital, Sichuan University

Zitieren

APA

Li, W., Yang, X., Chen, Q., Wang, Z., Duan, Y., & Chen, L. (2024). Monitoring levetiracetam concentration in saliva during pregnancy is stable and feasible. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14827

Vancouver

Li W, Yang X, Chen Q, Wang Z, Duan Y, Chen L. Monitoring levetiracetam concentration in saliva during pregnancy is stable and feasible. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14827

BibTeX
@article{Li2024,
  author = {Li, Wanling and Yang, Ximeng and Chen, Qian and Wang, Zhenlei and Duan, Yifei and Chen, Lei},
  title = {Monitoring levetiracetam concentration in saliva during pregnancy is stable and feasible},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  doi = {10.1111/cns.14827}
}
Kostenlos starten →